Drug and Device World: Rapid Nexus charts a new path for chronic wounds

In the shadow of a global diabetes epidemic and an aging population, chronic wounds—diabetic foot ulcers, venous leg ulcers, pressure injuries—represent a silent, growing, and devastating healthcare crisis. These are not simple cuts; they are complex biological failures where the healing process stalls, often indefinitely. The financial burden is staggering, with estimates for annual US wound care costs exceeding $28 billion. Most chillingly, chronic wounds are the leading cause of non-traumatic lower limb amputations, with a diabetic patient losing a limb every 22 seconds somewhere in the world. Rapid Nexus Nanotech Wound Solutions, a California-based medical-device developer, has approached the problem a different way. The company’s solutions focus on a different culprit: the degraded, ischemic, and denervated tissue surrounding the wound, known as the periwound. This “living edge” is often so compromised, in cases of chronic wounds, that it cannot orchestrate the complex cellular symphony required for closure. The result is a frustrating cycle of intervention and deterioration. The company recently secured a US Food and Drug Administration (FDA) 510(k) clearance for Hemastyl Gel, the first technology specifically engineered to treat this critical periwound tissue. In an interview with the Drug and Device World, Rapid Nexus’s CEO and founder, Dr. Margaret Kalmeta, detailed this revolutionary shift, explaining the science of the “dual-system,” the roadmap for patient access, and her ultimate vision: to make preventable amputations a relic of the past. Read full article

Citeline: Rapid Nexus Bets On Regeneration To Heal Wounds, Stop Amputations, Starting In VA Health Systems

Rapid Nexus hopes its regenerative wound-healing system can ease the burden of diabetic foot ulcers and amputations. Backed by early clinical data and $3.8m in seed funding, the start-up is targeting the VA as a launchpad into a $6.5bn US market, with FDA clearance expected later this year. California-based start-up Rapid Nexus wants to transform treatment for diabetic foot ulcers with its two-part regenerative wound-healing technology designed to treat open sores and prevent amputations, starting with patients at the Veterans Affairs system. Read full article

Yahoo Finance: Rapid Nexus Unveils First-Ever Medical Technology to Regrow Nerves and Stop Amputations in Diabetic Patients

This patented breakthrough is the first and only technology to treat dying tissue and regenerate nerves — restoring circulation, reversing chronic wounds, and preventing amputations for patients who previously had no options.  BREA, Calif., Sept. 23, 2025 /PRNewswire/ — Rapid Nexus, a California-based med-tech company, has unveiled the first medical device proven to regenerate nerves and reverse chronic wounds — offering a long-awaited solution for millions of patients at risk of limb loss from diabetes, trauma, and vascular disease. Chronic wounds are one of the most costly, overlooked, and deadly health issues facing diabetic and trauma patients today — and until now, there’s been no way to actually heal them. While the global wound care market surpasses $22.3 billion , current solutions — from wound vacs to skin grafts and antimicrobial creams — focus only on managing surface symptoms rather than addressing the root cause. As a result, tissue continues to deteriorate, infections deepen, and amputation often becomes the only remaining option. Rapid Nexus’s patented technology is the first to intervene at the source by regenerating nerve-damaged tissue and restoring circulation. It has also been shown to outperform leading antimicrobial products commonly used in diabetic amputation cases, without causing additional damage to surrounding healthy tissue. Read full article

Podcast Feature: Exploring Innovation in Wound Care

Dr. Margaret Kalmeta of Rapid Nexus Nanotech Wound Solutions, Inc. was recently featured on a podcast with Darwin Shurig at Shurig Solutions Inc., where she shared insights into the company’s innovative approach to wound care. Rapid Nexus has developed the industry’s first therapy designed specifically for the peri-wound, offering a non-invasive solution for healing chronic wounds. By treating the tissue surrounding the wound, this technology achieves outcomes that were once considered unattainable, demonstrating the potential of regenerative medicine to improve patient outcomes and quality of life. https://rapidnexus.com/wp-content/uploads/2023/12/1701472877240.mp4 Watch Full Interview

LSI: Rapid Nexus Secures Two New Patents in Q2

Rapid Nexus Nanotech Wound Solutions, Inc. (hashtag#LSIEurope23 Innovator) received two additional patents in Q2, bringing their total number of patents to four U.S. issued patents and six international issued patents. To date, Rapid Nexus has already proven to prevent amputations with their products. The company has developed a first of its kind nanotechnology wound dressing, along with devices that accelerate healing, to rapidly close chronic non-healing wounds. The wound treatment system consists of a nanotechnology wound gel dressing formulation (Hemastyl Rx®) and Gen-Ray®, a therapeutic heating device equipped with LEDs that increase the local blood circulation in order to accelerate the body’s reaction to Hemastyl Rx®. More recently, their wound product has also been shown to be 99.99% effective against Candida Auris, an emerging multidrug-resistant yeast. Congratulations to the Rapid Nexus team hitting these new milestones! This September we’ll be welcoming Dr. Margaret Kalmeta who has been selected to present Rapid Nexus at LSI Europe ‘23 in Barcelona Spain See Feature Here